

Hull and East Riding Prescribing Committee Minutes – Confirmed

| | |
|------------------------------|---|
| Date / Time | Wednesday 27 th March 2019, 1:00pm |
| Venue | The Board Room, Health House, Willerby |
| Chair | Dr S Raise, GP Prescribing Lead, ER |
| Notes / Action Points | Mrs W Hornsby, Senior Pharmacy Technician, HUTH |
| Quorate: Yes / No | Yes |

Mr A Ramirez, Professional Secretary, Senior Principal Pharmacist- Interface HUTH
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HUTH
Dr W Chong, Chief Pharmacist, HTFT
Mr K McCorry, Senior Pharmacist, NECS
Mr S Gaines, Senior Principal Pharmacist, HUTH
Dr R Schreiber, Medical Secretary, LMC
Mr G Hill, Senior Pharmacist, CHCP CIC
Mrs C Heyward, ERHLPC
Prof A Morice, Professor of Respiratory Medicine, HUTH

| | |
|------------------|--|
| Apologies | Mrs J Stark, Principal Pharmacist, HTFT Mr P Davis, Strategic Lead Primary Care, Hull, CCG Mrs J Clarke Chief Officer Local Pharmaceutical Committee ERHLPC Dr K Raghunath, GP Prescribing Lead, Hull CCG |
|------------------|--|

| Agenda No | Item | Discussion | Decision Made | Action | Lead | Due Date/Date complete |
|------------|---------------------------------|---|---|--|---|---|
| 2019.03.01 | Apologies | As above | | | | |
| 2019.03.02 | Declarations of Interest | RS declared that he was the GP lead for CHCP out of hours service | Noted | No further action | | 3/19 |
| 2019.03.03 | Minutes of the previous meeting | The last meeting was not quorate due to the absence of a HUTH clinician. AM approved all actions post meeting. | Noted | No further action | | 3/19 |
| 2019.03.04 | Action Tracker | <p>Dalteparin/Tinzaparin Switch HUTH has now reverted back to Dalteparin as its main LMWH.</p> <p>Supply Disruption Alert Epipen Epipen still available on name basis from suppliers. Emerade has now been added to formulary alongside Epipen. AR to discuss with immunology the use of adrenaline injectors based on the recommendation of the UK Rhesus Council. The committee requested the formulary to be updated with "prescribe by brand. Please make sure appropriate training is given on the device". CH agreed to chase manufacturers for training pens for use in community pharmacy.</p> <p>AOB AR has been monitoring the information on SCR regarding Red drugs and informed the committee that the trust were now beginning to see Red drugs appearing on SCRs. RS requested that if the situation did not keep improving he be informed to feedback to LMC.</p> <p>Correspondence Received Draft Continence Formulary has been approved by CHCP and is on agenda for discussion.</p> <p>Traffic Light Status WH has updated the red list</p> | <p>Noted</p> <p>Joint formulary to be updated</p> <p>CH to circulate information regarding training pens</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> | <p>No further action</p> <p>WH to update and add to intranet</p> <p>No further action</p> <p>No further action</p> | <p>AR</p> <p>WH</p> <p>CH</p> <p>AR</p> <p>WH</p> <p>WH</p> | <p>3/19</p> <p>5/19</p> <p>5/19</p> <p>3/19</p> <p>3/19</p> <p>3/19</p> |

| Agenda No | Item | Discussion | Decision Made | Action | Lead | Due Date/Date complete |
|-----------|------|--|--|--|--|---|
| | | <p>PG/SCF Renavit form has been added to website</p> <p>PG/SCF Self-Blood Glucose Monitoring Type 1&2 has been added to website</p> <p>PG/SCF Biological pathways for rheumatology, dermatology and gastroenterology all have been added to website</p> <p>PG/SCF Management of childhood asthma – comments to be discussed with consultants. Feedback to be given next time</p> <p>Transfer of Care AR discussed renal transplant medication repatriation with renal team. They believe it could lead to problems with compliance and adherence if patients have to receive the medicines and have the monitoring done at hospital, particularly if they live far away. Also they think there is an economical risk if all patients are repatriated and companies stop providing hospital discounts. Still an ongoing discussion.</p> <p>Correspondence Received AR has circulated “Items that should not be routinely prescribed “ document to relevant specialities at HUTH for comment</p> <p>Correspondence Received SR to write to PHE assistant director regarding public health emergencies, discuss next time.</p> <p>AOB AR has written draft SCF for Esmya which has been circulated to Mr Oboh and LMC for comments. Awaiting final by Mr Oboh before circulation to HERPC</p> | <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>AMB was not in attendance</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Agenda for May HERPC</p> | <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>Discuss next time</p> <p>No further action at this time</p> <p>Discuss next time</p> | <p>AR</p> <p>AR</p> <p>AR</p> <p>AMB</p> <p>AR</p> <p>AR</p> <p>SR</p> <p>AR</p> | <p>3/19</p> <p>3/19</p> <p>3/19</p> <p>3/19</p> <p>3/19</p> <p>3/19</p> <p>3/19</p> <p>3/19</p> |

| Agenda No | Item | Discussion | Decision Made | Action | Lead | Due Date/Date complete |
|------------|---|--|-------------------|------------------------------|------|------------------------|
| 2019.03.05 | Traffic Light Status | Linagliptin – AR will discuss with Jane Patmore updating T2D guideline | Approved as Blue | T2D guideline to be updated | AR | 5/19 |
| | | Inhaled Levofloxacin (Quinsair) | Approved as Red | Red list to be updated | WH | 5/19 |
| | | Apomorphine (Dacepton)- | Approved as amber | SCF to be updated | AR | 5/19 |
| | | Valganciclovir Liquid-Red | Approved as red | Red list to be updated | WH | 5/19 |
| | | Aprotonin –Red | Approved as red | Red list to be updated | WH | 5/19 |
| | | Semaglutide – will discuss with Jane Patmore place in guideline | Approved as blue | T2D guideline to be updated | AR | 5/19 |
| | | Tofacitinib- Red | Approved as red | Red list to be updated | WH | 5/19 |
| | | Hydrocortisone Granules – Green | Approved | WH to update joint formulary | WH | 5/19 |
| | | Emerade Adrenaline Autoinjector – Green | Approved | | WH | 5/19 |
| 2019.03.06 | Feedback From Commissioning Groups | Hull and ER CCG policies for Coeliac Disease: Policy on Prescribing of Gluten Free Products. Both policies were discussed and approved. Agenda items today. | Noted | | | 3/19 |
| 2019.03.07 | Prescribing guidelines, shared care frameworks for approval | UPDATES Pregabalin/Gabapentin Prescribing Guideline The guideline has been updated to include the new schedule 3 CD status. Prices updated and listed but agreed to remove them from document. | Approved | WH to add to website | WH | 5/19 |
| | | Understanding Pain Medicines Leaflet Changes include contraindications for Amitriptyline glaucoma and IOP and side effects associated with long term use. | Approved | WH to add to website | WH | 5/19 |
| | | | Approved | WH to add to website | WH | 5/19 |

| Agenda No | Item | Discussion | Decision Made | Action | Lead | Due Date/Date complete |
|-----------|------|--|----------------------------------|----------------------|-------|------------------------|
| | | <p>Medicines Prescribed in Pregnancy Changes to VT prophylaxis 10 days post C section</p> | Approved | WH to add to website | WH | 5/19 |
| | | <p>Medicines Requiring an ECG Reviewed. Date changed</p> | Approved | WH to add to website | WH | 5/19 |
| | | <p>VTE Medication on discharge Updated in view of NICE NG89 to include 16years old and above. Includes warning about possible problems with LMWH supplies.</p> | Approved | WH to add to website | WH | 5/19 |
| | | <p>Naltrexone Opioid Dependence Only change contact details</p> | Approved | WH to add to website | WH | 5/19 |
| | | <p>Naltrexone Alcohol Abuse Only change contact details</p> | Approved | WH to add to website | WH | 5/19 |
| | | <p>Acamprosate Alcohol Abuse Only change contact details</p> | Approved | WH to add to website | WH | 5/19 |
| | | <p>Continence Formulary Has now been approved by CHCP. AR would contact the urology dept at HUTH to inform them of the formulary so they are aware which products are recommended for use in primary care.</p> | Approved, AR to speak to urology | WH to add to website | WH | 5/19 |
| | | <p>Guideline for the Use of High Dose AntiPsychotic Therapy Reviewed. Date changed</p> | Approved | WH to add to website | WH | 5/19 |
| | | <p>ER CCG Coeliac Disease: Policy on Prescribing of Gluten Free Products Hull CCG Coeliac Disease: Policy on Prescribing of Gluten Free Products Two separate documents written as ER had approved 8 units per month Hull CCG has approved the Coeliac UK recommendations. SR commented that now that gluten free products are widely available in supermarkets it should be considered whether these products should still be available for prescription.</p> | Approved | WH to add to website | WH | 5/19 |
| | | <p>Medical Devices & Appliances Not Recommended for Routine Prescribing AR will distribute to relevant departments at HUTH for</p> | AR to distribute to HUTH | WH to add to website | WH/AR | 5/19 |

| Agenda No | Item | Discussion | Decision Made | Action | Lead | Due Date/Date complete |
|------------|---|--|---|---|------|------------------------|
| | | information/comment. There were concerns that vulnerable groups may not receive treatment depending on the interpretation of the document. CH said that the LPC were doing a lot of work around minor ailments and looking how to best serve vulnerable groups. Eg PGD for UTI treatment | | | | |
| 2019.03.08 | Regional Medicines Optimisation Committee | M+ E RMOC Update 2019: Issue 1 Medicines Governance Do Once Programme https://www.sps.nhs.uk/articles/maintaining-patency-of-central-venous-catheters-in-adults-rmoc-position-statement/ Secondary care does use heparinised saline in some care settings via PGD. | Noted | AR to discuss with relevant departments | AR | 5/19 |
| 2019.03.09 | Hull GP Collaborative | Controlled Drug Patient Contract & Opioid Leaflet Both documents brought to HERPC for comment/opinions. Although it was felt the documents were a tool that would be useful in some patients, there were issues with the contract content. The wording on the leaflet referring to the GP “obviously being partly responsible for prescribing” was also questioned. | RS will discuss with Andy Green before taking to LMC and GP collaborative permission. | | RS | 5/19 |
| 2019.03.10 | Correspondence Received | https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding.pdf The diabetes team and CCGs are in the process of discussing this new commissioning document. Keith Willet EU Exit Letter Medicines Supply Update Letter NLAG DOAC Proposal NLAG have sent a proposal from the cardiac network about using one DOAC as “preferred” agent at STP level. Potential high savings. A meeting will be held on 10 th April with attendance from all CCGs, hospital specialists and pharmacists. The clinical appropriateness of switching patients purely for financial benefit was questioned and SR asked what HUTH cardiologists thoughts were on this. SG informed the committee | AR/KM to feedback after the meeting | | AR | 5/19 |
| | | | Noted | | | |
| | | | Noted | | | |
| | | | AR to feedback at next HERPC meeting | | AR | 5/19 |

| Agenda No | Item | Discussion | Decision Made | Action | Lead | Due Date/Date complete |
|------------|------------------------------------|---|---|-------------------|------|------------------------|
| | | he has sent the proposal to HUTH cardiologists and stroke physicians for comments and that the document will also be discussed by HUTH Thrombosis committee. | | | | |
| 2019.03.11 | Primary Care Rebate Scheme | No rebates this month | | | | |
| 2019.03.12 | Additional Minutes for Information | a) MMIG (Jan) b) HEY D&T (Dec, Feb) c) HTFT DTC (Dec) d) CHCP e) Formulary Sub Group (Feb) f) York & Scarborough Medicines Commissioning Committee <ul style="list-style-type: none"> Dementia Care Pathway: Guidance for Prescribing Anticholinesterase Inhibitors & Memantine – Tee, Esk and Wear Valleys NHS Trust | Noted | No further action | | 5/19 |
| 2019.03.13 | A.O.B | The stock shortage of carbamazepine was raised. Mylan has informed community pharmacy's it will not be able to supply Carbagen IR 200mg and 400mg until mid 2019 and Carbagen 200mg and 400 mg MR until late 2019, therefore patients will need to be switched to alternative brand. Novartis has said production of Tegretol is unaffected and they will be able to support the additional demand. | CH will send AR the memo for circulation to HUTH clinicians | | CH | 5/19 |
| | Date and Time of Next Meeting | Wednesday 22 nd May 2019 1pm – 3pm, Board Room, Health House, Willerby, Hull | | | | |